MDXG Stock Overview
Develops and distributes placental tissue allografts for various sectors of healthcare. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
MiMedx Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$9.48 |
| 52 Week High | US$10.14 |
| 52 Week Low | US$5.47 |
| Beta | 1.98 |
| 1 Month Change | 2.49% |
| 3 Month Change | 60.68% |
| 1 Year Change | 8.10% |
| 3 Year Change | 51.20% |
| 5 Year Change | 35.43% |
| Change since IPO | 85.88% |
Recent News & Updates
We Think MiMedx Group (NASDAQ:MDXG) Can Manage Its Debt With Ease
Dec 23
We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease
Nov 21Recent updates
We Think MiMedx Group (NASDAQ:MDXG) Can Manage Its Debt With Ease
Dec 23We Ran A Stock Scan For Earnings Growth And MiMedx Group (NASDAQ:MDXG) Passed With Ease
Nov 21There's No Escaping MiMedx Group, Inc.'s (NASDAQ:MDXG) Muted Earnings Despite A 27% Share Price Rise
Nov 06MiMedx Group, Inc.'s (NASDAQ:MDXG) Shares Bounce 27% But Its Business Still Trails The Industry
May 21We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt
May 14Improved Revenues Required Before MiMedx Group, Inc. (NASDAQ:MDXG) Shares Find Their Feet
Mar 27We Think MiMedx Group (NASDAQ:MDXG) Can Stay On Top Of Its Debt
Jan 05MiMedx Group, Inc. (NASDAQ:MDXG) Stock Catapults 27% Though Its Price And Business Still Lag The Industry
Dec 18Is MiMedx Group (NASDAQ:MDXG) Using Debt In A Risky Way?
Aug 08Does MiMedx Group (NASDAQ:MDXG) Have A Healthy Balance Sheet?
Apr 22Health Check: How Prudently Does MiMedx Group (NASDAQ:MDXG) Use Debt?
Dec 20MiMedx gets Japanese reimbursement approval for its tissue allograft EPIFIX
Sep 12MiMedx Group expects AWC full-year sales in low end of 11%-14% growth range
Sep 06Shareholder Returns
| MDXG | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.3% | -1.7% | -1.1% |
| 1Y | 8.1% | -5.0% | 22.4% |
Return vs Industry: MDXG exceeded the US Biotechs industry which returned -3.4% over the past year.
Return vs Market: MDXG underperformed the US Market which returned 23.7% over the past year.
Price Volatility
| MDXG volatility | |
|---|---|
| MDXG Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: MDXG has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: MDXG's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2006 | 895 | Joe Capper | www.mimedx.com |
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins. The company’s patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization.
MiMedx Group, Inc. Fundamentals Summary
| MDXG fundamental statistics | |
|---|---|
| Market cap | US$1.38b |
| Earnings (TTM) | US$79.39m |
| Revenue (TTM) | US$342.80m |
17.5x
P/E Ratio4.1x
P/S RatioIs MDXG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDXG income statement (TTM) | |
|---|---|
| Revenue | US$342.80m |
| Cost of Revenue | US$57.01m |
| Gross Profit | US$285.80m |
| Other Expenses | US$206.41m |
| Earnings | US$79.39m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.54 |
| Gross Margin | 83.37% |
| Net Profit Margin | 23.16% |
| Debt/Equity Ratio | 10.5% |
How did MDXG perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 04:52 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
MiMedx Group, Inc. is covered by 13 analysts. 5 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Wittes | Aegis Capital Corporation |
| Jason Wittes | Brean Capital |
| William Plovanic | Canaccord Genuity |